AbbVie, Novartis and more win national coverage in China even as Pfizer's Paxlovid gets left out

Once again, biopharma companies offered hefty discounts to secure national reimbursement in China in the hopes that wider coverage in a fast-growing pharmaceutical market can offset price concessions. This time around, some companies are walking away with more deals than others.